<DOC>
	<DOCNO>NCT00559702</DOCNO>
	<brief_summary>The primary objective study compare pharmacokinetic ( PK ) pharmacodynamics ( PD ) single subcutaneous ( SC ) intramuscular ( IM ) dose 300 mg natalizumab intravenous ( IV ) administration 300 mg natalizumab multiple sclerosis ( MS ) participant . The secondary objective investigate safety , tolerability PK repeat natalizumab dos administer SC IM , investigate immunogenicity repeat natalizumab dos administer SC IM , explore proof concept within secondary progressive multiple sclerosis ( SPMS ) population use change baseline clinical measure include : expand disability status scale ( EDSS ) , multiple sclerosis functional composite scale ( MSFC ) , symbol digit modality test ( SDMT ) , visual analogue scale ( VAS ) , visual function test ; brain magnetic resonance imaging ( MRI ) measure include : number new newly-enlarging T2 hyperintense lesion , number new T1 hypointense lesion , number new gadolinium-enhancing ( Gd+ ) lesion , whole brain atrophy , magnetization transfer ratio ( MTR ) , diffusion tensor imaging ( DTI ) observe effect natalizumab administer IV SC brain MRI measure participant relapse form MS .</brief_summary>
	<brief_title>Safety Study Natalizumab Treat Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key For arm 1,2,3 4 : Diagnosis Secondary Progressive Multiple Sclerosis ( SPMS ) For arm 5 6 : Diagnosis relapse form Multiple Sclerosis ( MS ) . No past history receive natalizumab . Key For arm 1,2,3 4 Diagnosis primary progressive MS relapsingremitting MS. Form arm 5 6 : Diagnosis primary progressive MS secondary progressive MS without occurrence relapse . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>natalizumab</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>Tysabri Â®</keyword>
</DOC>